

Mercredi 16 novembre de 19h00 à 21h00,
au Palais des Congrès à Dijon
(3 boulevard de Champagne - 21078 DIJON CEDEX)
Salle Santenay-Chablis

19h00-19h10 : Stratégie du groupe (S. Delaloge)

19h10-19h40 : Résultats d'études du groupe en avant-première de SABCS

ADENDOM (S. Delaloge)

UCBG 2-14: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict[reg] (EPclin[reg]) clinico-genomic test on treatment decision making among patients with intermediate clinical risk

CARMINA02 (F. Lerebours)

Genomic analysis to evaluate response to neoadjuvant anastrozole and fulvestrant in post-menopausal ER-positive HER2-negative breast cancer patients included in the UCBG CARMINA02 trial

GRT02-COMET (J.Y. Pierga)

Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study

19h40-20h10: Essais en phase de lancement

ULTIMATE (F. André)

A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible to Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant

OPTIGEN (R. Rouzier)

Prospective multicenter randomized study assessing genomic test impact on shared decision of adjuvant chemotherapy in patients with ER-positive, Her2-negative early breast cancer with uncertainty on the indication of chemotherapy using standard assessments

PADA-1 (F.C. Bidard)

PAbociclib and hormone therapy as first line treatment for metastatic hormone-positive HER2-negative breast cancer: Efficacy, Safety and utility of Circulating ESR1mutation detection

20h10-20h35 : Actualité des essais en cours

RxPONDER (S. Delaloge); UNIRAD (T. Bachelot); SAFIR2 (F. André); NEOPAL (P. Cottu)

HYPOG01 (S. Rivera)

20h35-20h50 : Actualité du groupe des chirurgiens 15min (C. Coutant)

20h50 : Conclusion de la journée (S. Delaloge)

[21H00] Clôture de la séance